Predicine

Predicine offers a comprehensive suite of genomic profiling tests aimed at enhancing cancer diagnostics and monitoring. The company utilizes a sophisticated liquid biopsy platform that analyzes both cell-free DNA (cfDNA) and RNA (cfRNA) from blood or urine samples, providing critical molecular insights into cancer through advanced next-generation sequencing technologies. Predicine operates laboratories that are both CLIA-certified and CAP-accredited, located in the United States and China, ensuring high standards of clinical testing. The company supports biomarker-driven clinical trials across various phases (I to III) and has developed a proprietary platform, GeneRADAR, which assesses the genomic blueprint and functional biology of cancer from a single blood sample. Additionally, Predicine offers a specialized urine-based liquid biopsy test, particularly effective in detecting genitourinary cancers non-invasively. The firm’s use of AI-driven bioinformatics further enhances its capability to analyze complex genomic data. Predicine’s range of assays includes PredicineATLAS™, PredicineCARE™, PredicineRNA™, PredicineHEME™, PredicineBEACON™, and PredicineWES+™, each tailored for comprehensive and precise cancer profiling.